VISION AND MISSION

IN 10 YEARS

18.5 BILLION DOSES OF TREATMENT SUPPLIED

VISION

Our vision is a world in which people in need in low- and middle-income countries (LMICs) have rapid access to effective and affordable medical treatments and health technologies.

MISSION

Our mission is to increase access to, and facilitate the development of, life-saving medicines for LMICs through an innovative approach to voluntary licensing and patent pooling. We work with a range of partners — civil society, international organisations, industry, patient groups and governments — to prioritise and license novel and existing medicines and health technologies for people in these countries.
The public health terms and conditions in MPP licences seek to improve treatment options for the broadest number of people living in low- and middle-income countries (LMICs).

**Wide geographical scope**
over 140 countries benefitting from MPP’s licences

**Quality assured products**
strict quality assurance policies

**Non-exclusive**
to encourage generic competition

**Flexibility**
to adapt to circumstances and achieve public health goals

**Complementarity**
to other mechanisms and tools to facilitate access to treatments

**Licence management**
to monitor compliance and prevent market leakage

**Transparency:**
MPP’s licences are published on our website

**Waivers**
for data exclusivity
HOW WE WORK

PATENT HOLDERS

PATENT HOLDERS / ORIGINATOR PARTNERS

AbbVie
Bristol-Myers Squibb
Boehringer Ingelheim
F. Hoffmann-La Roche
Gilead Sciences
Janssen
Johns Hopkins University
Merck Sharp & Dohme
Pfizer
Pharco
ViiV Healthcare
University of Liverpool
United States National Institutes of Health

* Extension of non-enforcement policy
** Price agreement

GENERIC MANUFACTURING / PRODUCT DEVELOPMENT PARTNERS

Adcock Ingram
Anhui Biochem
Arene
Aurobindo
Beximco
Bili & Melinda Gates Medical Research Institute
Celtrion
Cipla
Desano
Emcure
Hetero
Langhua Pharma
Laurus Labs
Lupin
Macleods
Mangalam
Micro Labs
Natco
Strides Shasun
Sun Pharma
TB Alliance
Viatris (through its subsidiary Mylan)
Zydus Cadila

GENERIC MANUFACTURERS

MPP LICENCES MEDICINES TO GENERIC COMPANIES.

LICENSING TERMS ENCOURAGE THE DEVELOPMENT AND SUPPLY OF LOW-COST GENERIC VERSIONS IN LOW- AND MIDDLE-INCOME COUNTRIES

PEOPLE LIVING IN LOW- AND MIDDLE-INCOME COUNTRIES

HOW WE WORK

MPP LICENCES

(2010 - 2020)

abacavir (ABC) paediatric – part of the WHO-preferred treatment for children from three months to 10 years of age
atazanavir (ATV) – part of the WHO-preferred second-line treatment for adults and children
bictegravir (BIC) – an HIV integrase inhibitor approved by the U.S. FDA in 2018 as part of a single tablet regimen
cobicistat (COBI) – an enhancer to boost a number of antiretrovirals (ARVs) and potentially other drugs
dacabasvir (DAC) – part of the WHO-recommended pan-genotypic regimen – SOF + DAC – for the treatment of chronic hepatitis C
dolutegravir (DTG) adult – WHO-recommended as part of a preferred first-line regimen for adults
dolutegravir (DTG) paediatric – WHO-recommended as part of a preferred first-line regimen for infants and children of at least four weeks of age and weighing at least three kilograms
eviltegravir (EVI) – approved for use in children and adults as part of fixed-dose combinations
emtricitabine (FTC) – an important component of nucleoside reverse transcriptase inhibitors backbones, included in many of the WHO-recommended first- and second-line treatments for children and adults
glecaprevir/pibrentasvir (G/P) – WHO-recommended pan-genotypic treatment for chronic hepatitis C
lopinavir, ritonavir (LPV/r) – WHO-recommended as one of the preferred second-line options for adults
lopinavir, ritonavir (LPV/r) paediatric – WHO-recommended component of the preferred first- and second-line option for children
patents-related to darunavir (DRV) – MPP’s first licence signed with the U.S. National Institutes of Health; darunavir/ritonavir (r) is recommended by WHO as part of the alternative second-line option
raltegravir (RAL) paediatric – recommended by WHO as preferred first-line treatment for newborns, and alternative first-line option for infants and children for whom approved DTG dosing is not yet available
ravidasvir (RAV) – an investigational drug for chronic hepatitis C
solid drug nanoparticle technology – a technology that reformulates poorly soluble and insoluble drugs into water-dispersible formulations to improve delivery into the body, thereby reducing its oral dosage
sutezolid – an investigational drug for tuberculosis
tenofovir alafenamide (TAF) – WHO-recommended as an alternative first-line HIV treatment option in children and in special circumstances in adults; also approved for HIV PrEP and for the treatment of chronic hepatitis B in adults
tenofovir disoproxil fumarate (TDF) – WHO-recommended as part of a preferred first-line HIV treatment for adults and children, as an option for second-line treatment, for HIV PrEP and for the treatment of chronic hepatitis B infection
valganciclovir* – oral medicine to treat or prevent cytomegalovirus disease, a common HIV co-infection

* Price agreement

HIV
Hepatitis C
Tuberculosis

THE MEDICINES PATENT POOL (MPP) | ANNUAL REPORT 2020